The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
LLM 2021 | Actionable pathways that could be targeted in myeloma
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses interesting and promising actionable pathways that could be targeted in the treatment of multiple myeloma. The development of compounds targeting genes such as MMSET, associated with the translocation t(4; 14), is currently in its early stages. Agents targeting RAS mutations are also under development. Additionally, targeting the BRAF mutation may be of interest in myeloma as well. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
